<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737047</url>
  </required_header>
  <id_info>
    <org_study_id>CRO: 1992</org_study_id>
    <secondary_id>2012-003581-40</secondary_id>
    <nct_id>NCT01737047</nct_id>
  </id_info>
  <brief_title>The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'</brief_title>
  <acronym>POPPY</acronym>
  <official_title>A Prospective, Observational Study to Examine the Effects of Ageing on the Clinical Outcomes of People Living With HIV in England and Ireland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify medical conditions that may cause particular&#xD;
      problems to individuals receiving care for HIV infection over the age of 50. In addition, as&#xD;
      the effects and potentially the side effects, of HIV medication may change with age, this&#xD;
      study will also investigate the association between age and differing effects of&#xD;
      antiretroviral therapies such as treatment outcomes, side effects and the levels of drugs in&#xD;
      blood.&#xD;
&#xD;
      Results from this study may inform future HIV treatment guidelines on how we monitor&#xD;
      individuals with HIV infection. The results may also assist in the design of future studies&#xD;
      for the treatment of diseases associated with ageing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre, prospective, observational study over 3 years.&#xD;
&#xD;
      Our study will describe the impact of advancing age on the experience of living with HIV in&#xD;
      England and Ireland. To address this we will establish cohorts of HIV-positive people aged&#xD;
      &gt;50 and &lt;50 years as well as demographically matched HIV-negative people aged &gt;50 years.&#xD;
&#xD;
        1. To analyse the incidence and outcomes of co-morbidities in older-HIV-positive people and&#xD;
           their relationship with demographic/clinical factors.&#xD;
&#xD;
        2. To evaluate associations between antiretroviral drug concentrations and age, and to&#xD;
           assess the potential impact of age on drug efficacy, drug-drug interactions and&#xD;
           co-morbidities.&#xD;
&#xD;
        3. To contribute to the development and implementation of evidence-based recommendations&#xD;
           for the clinical monitoring of older HIV-positive patients.&#xD;
&#xD;
      2000 will be recruited in all either white or black african individuals (self reported) 1000&#xD;
      will be Over 50 years of age and HIV positive, 500 will be under the age of 50 and will be&#xD;
      HIV positive and 500 will be over the age of 50 and be HIV negative.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>clinical manifestations of ageing</measure>
    <time_frame>after 2 years</time_frame>
    <description>To analyse the incidence and outcomes of co-morbidities in older-HIV-positive people and their relationship with demographic/clinical factors.Comparison of three groups HIV+ve &gt;50, HIV+&lt;50 and HIV-ve &gt;50. White or black african - analysis of demographic details and co-morbidity details collected at each visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>variations of anti-retroviral medication associated with age.</measure>
    <time_frame>after 2 years</time_frame>
    <description>Comparison of two groups HIV+ve &gt;50 and HIV+ &lt;50 measurement of blood concentrations of HIV medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess the potential impact of age on drug efficacy, drug-drug interactions and co-morbidities.</measure>
    <time_frame>two years</time_frame>
    <description>Comparison of three groups HIV+ve &gt;50, HIV+&lt;50 and HIV-ve &gt;50. Drug related side effects collected at each visit and also Co-morbidity details collected at each visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To contribute to the development and implementation of evidence-based recommendations for the clinical monitoring of older HIV-positive patients.</measure>
    <time_frame>after 2 years</time_frame>
    <description>Comparison of co-morbidities in relation to age in the three groups: HIV+ve &gt;50, HIV+ve &lt;50 and HIV -ve &gt;50.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1377</enrollment>
  <condition>HIV Positive</condition>
  <condition>Ageing</condition>
  <arm_group>
    <arm_group_label>HIV positive over 50 years of age</arm_group_label>
    <description>All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.&#xD;
Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV positive under the age of 50</arm_group_label>
    <description>All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.&#xD;
Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV negative over the age of 50</arm_group_label>
    <description>All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood for storage Blood (serum and plasma,) and urine samples will be collected at visits 1&#xD;
      and 3 stored for subsequent projects of the potential pathogenic mechanisms underlying&#xD;
      age-related diseases. This will include assessment of vitamin-D and PTH and probably DNA&#xD;
      analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV positive over 50 years HIV positive between 18 and 50 years HIV negative over 50 years&#xD;
        White Black african&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Older HIV-positive cohort (n=1000):&#xD;
&#xD;
          -  documented HIV infection&#xD;
&#xD;
          -  age &gt;50 years at study entry&#xD;
&#xD;
          -  self defined white or black African ethnicity&#xD;
&#xD;
          -  likely route of HIV acquisition via sexual exposure Either by male to male exposure if&#xD;
             white or by heterosexual exposure if white or black African&#xD;
&#xD;
          -  able to comprehend study patient information leaflet&#xD;
&#xD;
             -Younger HIV-positive cohort (n=500):&#xD;
&#xD;
          -  documented HIV infection&#xD;
&#xD;
          -  age &lt;50 at study entry*&#xD;
&#xD;
          -  self defined white or black African ethnicity&#xD;
&#xD;
          -  likely route of HIV acquisition via sexual exposure Either by male to male exposure if&#xD;
             white or by heterosexual exposure if white or black African.&#xD;
&#xD;
          -  able to comprehend study patient information leaflet&#xD;
&#xD;
               -  this group will comprise of at least 150 subjects in each of the following age&#xD;
                  groups: 20-29, 30-39, 40-49 years. Recruitment will be monitored by the Study&#xD;
                  Monitoring Team.&#xD;
&#xD;
        HIV-negative cohort (n=500):&#xD;
&#xD;
          -  documented negative HIV test at screening&#xD;
&#xD;
          -  age &gt;50 years at study entry&#xD;
&#xD;
          -  self defined white or black African ethnicity&#xD;
&#xD;
          -  registered with a General Practitioner and gives permission for contact with that&#xD;
             General Practitioner.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  in the opinion of the investigator, those unable or unwilling to comply with the&#xD;
             requirements of the study&#xD;
&#xD;
          -  life expectancy less than 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Sabine, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Winston, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University College Dublin School of Medicine and Medical Sciences, Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homerton University Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Marys Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College NHS Trust</name>
      <address>
        <city>London</city>
        <zip>WC1E 6JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>De Francesco D, Underwood J, Post FA, Vera JH, Williams I, Boffito M, Sachikonye M, Anderson J, Mallon PW, Winston A, Sabin CA; POPPY study group. Defining cognitive impairment in people-living-with-HIV: the POPPY study. BMC Infect Dis. 2016 Oct 28;16(1):617.</citation>
    <PMID>27793128</PMID>
  </results_reference>
  <results_reference>
    <citation>Underwood J, De Francesco D, Post FA, Vera JH, Williams I, Boffito M, Mallon PW, Anderson J, Sachikonye M, Sabin C, Winston A; Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study group. Associations between cognitive impairment and patient-reported measures of physical/mental functioning in older people living with HIV. HIV Med. 2017 May;18(5):363-369. doi: 10.1111/hiv.12434. Epub 2016 Oct 26.</citation>
    <PMID>27785907</PMID>
  </results_reference>
  <results_reference>
    <citation>Bagkeris E, Burgess L, Mallon PW, Post FA, Boffito M, Sachikonye M, Anderson J, Asboe D, Garvey L, Vera J, Williams I, Johnson M, Babalis D, De Francesco D, Winston A, Sabin CA. Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study. Int J Epidemiol. 2018 Oct 1;47(5):1391-1392e. doi: 10.1093/ije/dyy072.</citation>
    <PMID>29746638</PMID>
  </results_reference>
  <results_reference>
    <citation>Underwood J, De Francesco D, Leech R, Sabin CA, Winston A; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study. Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. PLoS One. 2018 Apr 11;13(4):e0194760. doi: 10.1371/journal.pone.0194760. eCollection 2018.</citation>
    <PMID>29641619</PMID>
  </results_reference>
  <results_reference>
    <citation>Sabin CA, Harding R, Bagkeris E, Nkhoma K, Post FA, Sachikonye M, Boffito M, Anderson J, Mallon PWG, Williams I, Vera J, Johnson M, Babalis D, Winston A. Pain in people living with HIV and its association with healthcare resource use, well being and functional status. AIDS. 2018 Nov 28;32(18):2697-2706. doi: 10.1097/QAD.0000000000002021.</citation>
    <PMID>30289809</PMID>
  </results_reference>
  <results_reference>
    <citation>De Francesco D, Verboeket SO, Underwood J, Bagkeris E, Wit FW, Mallon PWG, Winston A, Reiss P, Sabin CA; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study and the AGEhIV Cohort Study. Patterns of Co-occurring Comorbidities in People Living With HIV. Open Forum Infect Dis. 2018 Oct 24;5(11):ofy272. doi: 10.1093/ofid/ofy272. eCollection 2018 Nov.</citation>
    <PMID>30465014</PMID>
  </results_reference>
  <results_reference>
    <citation>Pool E, Winston A, Bagkeris E, Vera JH, Mallon P, Sachikonye M, Post FA, Pozniak A, Boffito M, Anderson J, Williams I, Johnson M, Burgess L, Sabin CA; Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study team. High-risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV-positive men who have sex with men. HIV Med. 2019 Feb;20(2):131-136. doi: 10.1111/hiv.12690. Epub 2018 Dec 12.</citation>
    <PMID>30548745</PMID>
  </results_reference>
  <results_reference>
    <citation>Halloran MO, Boyle C, Kehoe B, Bagkeris E, Mallon P, Post FA, Vera J, Williams I, Anderson J, Winston A, Sachikonye M, Sabin C, Boffito M. Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study. Antivir Ther. 2019;24(3):193-201. doi: 10.3851/IMP3293.</citation>
    <PMID>30700636</PMID>
  </results_reference>
  <results_reference>
    <citation>De Francesco D, Underwood J, Bagkeris E, Boffito M, Post FA, Mallon P, Vera JH, Williams I, Anderson J, Johnson M, Sabin CA, Winston A; Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study. Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls. HIV Med. 2019 Apr;20(4):274-285. doi: 10.1111/hiv.12714. Epub 2019 Feb 8.</citation>
    <PMID>30734983</PMID>
  </results_reference>
  <results_reference>
    <citation>De Francesco D, Winston A, Underwood J, Cresswell FV, Anderson J, Post FA, Williams I, Mallon PW, Sachikonye M, Babalis D, Vera JH, Bagkeris E, Milinkovic A, Sabin CA. Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals. Int J STD AIDS. 2019 Apr;30(5):440-446. doi: 10.1177/0956462418817612. Epub 2019 Jan 10.</citation>
    <PMID>30999830</PMID>
  </results_reference>
  <results_reference>
    <citation>Dhillon S, Sabin CA, Alagaratnam J, Bagkeris E, Post FA, Boffito M, Anderson J, Vera J, Williams I, Johnson M, Sachikonye M, Babalis D, Mallon PW, Winston A; Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study. Level of agreement between frequently used cardiovascular risk calculators in people living with HIV. HIV Med. 2019 May;20(5):347-352. doi: 10.1111/hiv.12731. Epub 2019 Mar 14.</citation>
    <PMID>30873751</PMID>
  </results_reference>
  <results_reference>
    <citation>De Francesco D, Underwood J, Bagkeris E, Anderson J, Williams I, Vera JH, Post FA, Boffito M, Johnson M, Mallon PWG, Winston A, Sabin CA; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study. Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. AIDS. 2019 Oct 1;33(12):1871-1880. doi: 10.1097/QAD.0000000000002293.</citation>
    <PMID>31259766</PMID>
  </results_reference>
  <results_reference>
    <citation>Savinelli S, De Francesco D, Feeney ER, Babalis D, Bagkeris E, Post FA, Boffito M, Williams I, Vera J, Johnson M, Anderson J, Sachikonye M, Winston A, Sabin C, Mallon P. Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross-sectional analysis. HIV Med. 2020 Aug;21(7):441-452. doi: 10.1111/hiv.12857. Epub 2020 Apr 20.</citation>
    <PMID>32311831</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Boffito M, Dickinson L, Bagkeris E, Khoo S, Post FA, Vera J, Williams I, Ndoutoumou A, Anderson J, Mallon P, McClure M, Winston A, Sabin C; POPPY Study. Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV. AIDS. 2020 Apr 1;34(5):790-793. doi: 10.1097/QAD.0000000000002479.</citation>
    <PMID>32167992</PMID>
  </results_reference>
  <results_reference>
    <citation>Sabin CA, Kunisaki KM, Bagkeris E, Post FA, Sachikonye M, Boffito M, Anderson J, Mallon P, Williams I, Vera JH, Johnson M, Babalis D, Winston A. Respiratory symptoms and chronic bronchitis in people with and without HIV infection. HIV Med. 2021 Jan;22(1):11-21. doi: 10.1111/hiv.12955. Epub 2020 Sep 6.</citation>
    <PMID>32892488</PMID>
  </results_reference>
  <results_reference>
    <citation>Sabin CA, Harding R, Bagkeris E, Geressu A, Nkhoma K, Post FA, Sachikonye M, Boffito M, Anderson J, Mallon PWG, Williams I, Vera J, Johnson MA, Babalis D, Winston A. The predictors of pain extent in people living with HIV. AIDS. 2020 Nov 15;34(14):2071-2079. doi: 10.1097/QAD.0000000000002660.</citation>
    <PMID>32773481</PMID>
  </results_reference>
  <results_reference>
    <citation>Winston A, De Francesco D, Post F, Boffito M, Vera J, Williams I, Anderson J, Mallon PWG, Sabin CA; POPPY Study Group. Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes. AIDS. 2020 Oct 1;34(12):1795-1800. doi: 10.1097/QAD.0000000000002606.</citation>
    <PMID>32732634</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 1, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Ageing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

